This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 955756.

Prof. Christos Reppas

National and Kapodistrian University of Athens, Department of Pharmacy, Section of Pharmaceutical Technology (NKUA), Greece

Professor in Pharmaceutics at National and Kapodistrian University of Athens, Department of Pharmacy

WP2 Co-Leader, Supervisor of ESR9


Christos Reppas is Professor in Pharmaceutics, Department of Pharmacy, National and Kapodistrian University of Athens (NKUA), Greece. He received his Pharmacy Degree from NKUA in 1982 and his PhD in 1986 in Pharmaceutical Sciences from the same University. From 1988 to 1989 he completed a postdoctoral fellowship in Pharmaceutics at the University of Michigan (USA). He joined NKUA in 1989 as a Lecturer. He has held research positions with the University of London (UK), the University of Michigan (USA), Glaxo R&D (UK) and the University of Frankfurt/Main (Germany). Research interests focus to the effects of dosage form characteristics and of gastrointestinal physiology on intraluminal performance of xenobiotics and the development of in vitro tests that are predictive of the intraluminal dosage form and drug performance. He has supervised 13 completed PhD Theses. He is co-author of more than 140 peer reviewed papers and chapters in international journals and books, two books in Biopharmaceutics and Drug Disposition and one patent (h-index 46). He is member of the editorial board of AAPS Journal, European Journal of Pharmaceutical Sciences, Journal of Pharmacy and Pharmacology, and Journal of Drug Delivery Science and Technology. He is/has been PI in several EU funded training and research programs (OrBiTo, PEARRL, COLOTAN, AGePOP) and one COST action (UNGAP, vice-chair).

Selected Publications

  • Pentafragka C, Vertzoni M, Dressman J, Symillides M, Goumas K, Reppas C. Characteristics of contents in the upper gastrointestinal lumen after a standard high-calorie high-fat meal and implications for the in vitro drug product performance testing conditions. Eur J Pharm Sci. 2020 Dec 1;155:105535. doi: 10.1016/j.ejps.2020.105535. Epub 2020 Aug 30. PMID: 32877722.
  • Pentafragka C, Vertzoni M, Symillides M, Goumas K, Reppas C. Disposition of two highly permeable drugs in the upper gastrointestinal lumen of healthy adults after a standard high-calorie, high-fat meal. Eur J Pharm Sci. 2020 Apr 18;149:105351. doi: 10.1016/j.ejps.2020.105351. Epub ahead of print. PMID: 32311455.
  • Pentafragka C, Symillides M, McAllister M, Dressman J, Vertzoni M, Reppas C. The impact of food intake on the luminal environment and performance of oral drug products with a view to in vitro and in silico simulations: a PEARRL review. J Pharm Pharmacol. 2019 Apr;71(4):557-580. doi: 10.1111/jphp.12999. Epub 2018 Sep 11. PMID: 30203429.
  • Vinarov Z, Abdallah M, Agundez JAG, Allegaert K, Basit AW, Braeckmans M, Ceulemans J, Corsetti M, Griffin BT, Grimm M, Keszthelyi D, Koziolek M, Madla CM, Matthys C, McCoubrey LE, Mitra A, Reppas C, Stappaerts J, Steenackers N, Trevaskis NL, Vanuytsel T, Vertzoni M, Weitschies W, Wilson C, Augustijns P. Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review. Eur J Pharm Sci. 2021 Jul 1;162:105812. doi: 10.1016/j.ejps.2021.105812. Epub 2021 Mar 20. PMID: 33753215